Backache — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for backache. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
2
Active US patents
52/100
Avg vulnerability
—
Annual revenue covered

Originators in Backache

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Averitas 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating backache. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
28
1
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Qutenza
CAPSAICIN
 Averitas 2 52 — 2028-12-15

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9226903 Qutenza formulation 55 2028-12-15
8821920 Qutenza formulation 48 2030-03-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8821920 Qutenza formulation 48 2030-03-26
9226903 Qutenza formulation 55 2028-12-15

Related